新辅助来曲唑联合Taselisib对比来曲唑联合安慰剂治疗绝经后ER阳性HER2阴性早期乳腺癌(LORELEI):多中心随机双盲安慰剂对照2期试验
LORELEI试验纳入334例绝经后ER阳性HER2阴性早期乳腺癌患者,随机接受来曲唑联合Taselisib或安慰剂新辅助治疗16周。Taselisib组客观缓解率显著提高(50% vs 39%),尤其在PIK3CA突变亚组(56% vs 38%),但病理完全缓解率无显著差异。
要点
- 病理完全缓解率两组无显著差异,总人群3% vs 1%。
- Taselisib组3-4级不良事件以胃肠道、感染和皮肤皮下组织疾病多见。
核心结论
- 在绝经后ER阳性HER2阴性早期乳腺癌新辅助治疗中,来曲唑联合Taselisib较来曲唑联合安慰剂显著提高客观缓解率,但未显著提高病理完全缓解率。
研究设计与样本
- 多中心、随机、双盲、平行队列、安慰剂对照2期试验,纳入85家医院22个国家的334例绝经后ER阳性HER2阴性I-III期可手术乳腺癌患者。
- 随机分层因素为肿瘤大小和淋巴结状态,主要终点为乳腺MRI中心评估的客观缓解率和手术时乳腺及腋窝局部评估的病理完全缓解率。
主要发现
- Taselisib组最常见3-4级不良事件为胃肠道13/167(8%)、感染8/167(5%)、皮肤皮下组织疾病8/167(5%)。
临床怎么用
- 对于绝经后ER阳性HER2阴性早期乳腺癌,新辅助来曲唑联合Taselisib可提高客观缓解率,尤其PIK3CA突变患者,但未转化为病理完全缓解率提高。
- 治疗期间需关注胃肠道、感染及皮肤皮下组织等3-4级不良事件。
局限性
- 病理完全缓解率事件数少,置信区间宽。
- 研究仅纳入绝经后女性,结果不能外推至其他人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endocrine therapy-based neoadjuvant treatment for luminal breast cancer allows efficient testing of new combinations before surgery. The activation of the phosphatidylinositol-3-kinase (PI3K) pathway is a known mechanism of resistance to endocrine therapy. Taselisib is an oral, selective PI3K inhibitor with enhanced activity against PIK3CA-mutant cancer cells. The LORELEI trial tested whether taselisib in combination with letrozole would result in an increased proportion of objective responses and pathological complete responses. METHODS: In this multicentre, randomised, double-blind, parallel-cohort, placebo-controlled phase 2, study, we enrolled postmenopausal women (aged ≥18 years) with histologically confirmed, oestrogen receptor (ER)-positive, HER2-negative, stage I-III, operable breast cancer, from 85 hospitals in 22 countries worldwide. To be eligible, patients had have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1, adequate organ function, and had to have evaluable tumour tissue for PIK3CA genotyping. Patients were randomly assigned (1:1) by means of a permuted block algorithm (block size of four) via an interactive voice or web-based response system, to receive letrozole (2·5 mg/day orally, continuously) with either 4 mg of oral taselisib or placebo (on a 5 days-on, 2 days-off schedule) for 16 weeks, followed by surgery. Randomisation was stratified by tumour size and nodal status. Site staff, patients, and the sponsor were masked to treatment assignment. Coprimary endpoints were the proportion of patients who achieved an objective response by centrally assessed breast MRI and a locally assessed pathological complete response in the breast and axilla (ypT0/Tis, ypN0) at surgery in all randomly assigned patients and in patients with PIK3CA-mutant tumours. Analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT02273973, and is closed to accrual. FINDINGS: Between Nov 12, 2014, and Aug 12, 2016, 334 participants were enrolled and randomly assigned to receive letrozole and placebo (n=168) or letrozole and taselisib (n=166). Median follow-up was 4·9 months (IQR 4·7-5·1). The study met one of its primary endpoints: the addition of taselisib to letrozole was associated with a higher proportion of patients achieving an objective response in all randomly assigned patients (66 [39%] of 168 patients in the placebo group vs 83 [50%] of 166 in the taselisib group; odds ratio [OR] 1·55, 95% CI 1·00-2·38; p=0·049) and in the PIK3CA-mutant subset (30 [38%] of 79 vs 41 [56%] of 73; OR 2·03, 95% CI 1·06-3·88; p=0·033). No significant differences were observed in pathological complete response between the two groups, either in the overall population (three [2%] of 166 in the taselisib group vs one [1%] of 168 in the placebo group; OR 3·07 [95% CI 0·32-29·85], p=0·37) or in the PIK3CA-mutant cohort (one patient [1%) vs none [0%]; OR not estimable, p=0·48). The most common grade 3-4 adverse events in the taselisib group were gastrointestinal (13 [8%] of 167 patients), infections (eight [5%]), and skin-subcutaneous tissue disorders (eight [5%]). In the placebo group, four (2%) of 167 patients had grade 3 or worse vascular disorders, two (1%) had gastrointestinal disorders, and two (1%) patients had grade 3 or worse infections and infestations. There was no grade 4 hyperglycaemia and grade 3 cases were asymptomatic. Serious adverse events were more common in the taselisib group (eight [5%] patients with infections and seven [4%] with gastrointestinal effects) than in the placebo group (one [1%] patient each with grade 3 postoperative wound and haematoma infection, grade 4 hypertensive encephalopathy, grade 3 acute cardiac failure, and grade 3 breast pain). One death occurred in the taselisib group, which was not considered to be treatment-related. INTERPRETATION: The increase in the proportion of patients who achieved an objective response from the addition of taselisib to endocrine therapy in a neoadjuvant setting is consistent with the clinical benefit observed in hormone receptor-positive, HER2-negative, metastatic breast cancer. FUNDING: Genentech and F Hoffmann-La Roche.
引用
- Saura C, Hlauschek D, Oliveira M, et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2019. PMID: 31402321. doi:10.1016/S1470-2045(19)30334-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。